

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[NT012 trade name]*

Albendazole 400 mg chewable tablets

[NT012 trade name], manufactured at Medopharm Private Limited, Tamil Nadu, India, was included in the WHO list of prequalified medicinal products for the treatment of neglected tropical diseases on 25 December 2024.

[NT012 trade name] is indicated for treatment of certain helminthic infections. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [NT012 trade name] is albendazole.

The efficacy and safety of albendazole is well established based on extensive clinical experience in the treatment of helminthic infections.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of albendazole in the treatment of certain helminthic infections, the team of assessors advised that [NT012 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [NT012 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [NT012 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Initial acceptance	Date	Outcome
Status on PQ list	25 December 2024	listed
Pharmaceutical quality	24 December 2024	MR
Bioequivalence	14 December 2024	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	02 September 2022	MR
FPP	12 November 2021	MR
GCP/GLP (re-)inspection	04 January 2024	MR*
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard]	GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification	